coagulation platelet aggretion
Conditions
Interventions
Administration of aspirin (6 days, 75 mg per day)
Sponsors
Centre for Human Drug Research
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Male subject of 18-55 years of age (inclusive); -Have a Body Mass Index (BMI) between 18 and 32 kg/m2 (inclusive) and body weight between 50 kg and 90 kg (inclusive);
Exclusion criteria
Exclusion criteria: -Clinically relevant abnormal history of physical and mental health as determined by medical history taking and physical examinations obtained during the screening visit and/or at the start of the first study day (as judged by the investigator); -Clinically relevant abnormal laboratory results, ECG and vital signs, or physical findings at screening and/or at the start of the first study day (as judged by the investigator); -Positive test for hepatitis B, C or HIV ; -Subjects with abnormal bleeding time at screening -Subjects with history of gastrointestinal bleeding, recurrent nose bleeds, easy bruising; -History of alcoholism or substance abuse within three years prior to screening - history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food; -Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary: whole blood platelet aggregation | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary: -bleeding time, APPT, PT, ACT, TGT, factor Xa generation -Urinary TG, TAT, and creatinine | — |
Countries
Netherlands
Outcome results
None listed